Publications by authors named "Merin Elizabeth Kuruvilla"

4 Publications

  • Page 1 of 1

Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration.

Clin Infect Dis 2021 May 14. Epub 2021 May 14.

Division of Pulmonary, Allergy and Critical Care, Emory University School of Medicine, Atlanta, Georgia, U.S.A.

Addressing COVID19 vaccine hesitancy and minimizing potential vaccine contraindications are critical to combat the ongoing pandemic. We describe a practical approach to immediate adverse events after the first dose of the SARS-CoV2 mRNA vaccines, focusing on allergic reactions with respect to their diagnosis and management.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/ciab448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194535PMC
May 2021

Direct amoxicillin challenge without preliminary skin testing for pediatric patients with penicillin allergy labels.

Ann Allergy Asthma Immunol 2020 08 11;125(2):226-228. Epub 2020 May 11.

Department of Pediatrics, Emory University, Atlanta, Georgia; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, Georgia; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University School of Medicine, Atlanta, Georgia. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2020.05.004DOI Listing
August 2020

Iodinated contrast media hypersensitivity: recommendations for the pain practitioner.

Reg Anesth Pain Med 2019 Jul 15. Epub 2019 Jul 15.

Department of Pulmonary, Allergy, Critical Care & Sleep, Emory University, Atlanta, Georgia, USA

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/rapm-2019-100625DOI Listing
July 2019

Treatment of refractory mastocytic enterocolitis with budesonide.

J Gastrointestin Liver Dis 2018 Sep;27(3):327-329

Department of Pathology, Emory University, Atlanta, Georgia, USA.

Mast cells (MCs) are being increasingly implicated as a possible contributor to symptoms in diarrhea predominant irritable bowel syndrome (IBS). The term "mastocytic enterocolitis" was proposed to describe an increase in mucosal MCs in patients with chronic diarrhea due to functional gastrointestinal disease (FGID). The efficacy of anti-MC mediator therapy (antihistamines and MC stabilizers) has been well documented in this setting. Here we describe the treatment with oral budesonide of mastocytic enterocolitis refractory to standard anti-MC therapy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.15403/jgld.2014.1121.273.dhaDOI Listing
September 2018